U.S. Sepsis Therapeutics Market Size & Outlook, 2025-2030
Related Markets
U.S. sepsis therapeutics market highlights
- The U.S. sepsis therapeutics market generated a revenue of USD 1,376.1 million in 2024 and is expected to reach USD 1,934.3 million by 2030.
- The U.S. market is expected to grow at a CAGR of 5.9% from 2025 to 2030.
- In terms of segment, cephalosporin was the largest revenue generating drug class in 2024.
- Glycopeptide is the most lucrative drug class segment registering the fastest growth during the forecast period.
Sepsis therapeutics market data book summary
| Market revenue in 2024 | USD 1,376.1 million |
| Market revenue in 2030 | USD 1,934.3 million |
| Growth rate | 5.9% (CAGR from 2025 to 2030) |
| Largest segment | Cephalosporin |
| Fastest growing segment | Glycopeptide |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cephalosporin, Aminoglycosides, Glycopeptide, Other Drug Class |
Other key industry trends
- In terms of revenue, U.S. accounted for 34.9% of the global sepsis therapeutics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. sepsis therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 36.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Sepsis Therapeutics Market Scope
Sepsis Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Aridis Pharmaceuticals | View profile | 11-50 | San Jose, California, United States, North America | http://aridispharma.com/ |
| Pfizer, Inc. | View profile | - | - | - |
| Eli Lilly and Company | View profile | - | - | - |
| La jolla Pharmaceutical | View profile | 101-250 | San Diego, California, United States, North America | https://www.lajollapharmaceutical.com |
| AstraZeneca PLC ADR | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| T2 Biosystems Inc | View profile | 113 | 101 Hartwell Avenue, Lexington, MA, United States, 02421 | https://www.t2biosystems.com |
| Astellas Pharma Inc | View profile | 14484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | http://www.astellas.com |
| Asahi Kasei Corp | View profile | 48897 | 1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo, Japan, 101-8101 | http://www.asahi-kasei.co.jp |
| GSK PLC ADR | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
U.S. sepsis therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to sepsis therapeutics market will help companies and investors design strategic landscapes.
Cephalosporin was the largest segment with a revenue share of 63.91% in 2024. Horizon Databook has segmented the U.S. sepsis therapeutics market based on cephalosporin, aminoglycosides, glycopeptide, other drug class covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to U.S. sepsis therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. sepsis therapeutics market databook
-
Our clientele includes a mix of sepsis therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. sepsis therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. sepsis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. sepsis therapeutics market size, by drug class, 2018-2030 (US$M)
U.S. Sepsis Therapeutics Market Outlook Share, 2024 & 2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
